Concepedia

Christopher J. Zopf

CJ

Statistics

Publications

4

Citations

161

H-Index

4

Active since

2017

Affiliations

Pfizer (United States)(Current)

Huntsman Cancer Institute

The University of Texas MD Anderson Cancer Center

Tennessee Oncology

Comprehensive Cancer Centers of Nevada

Christopher J. Zopf is an author at Pfizer (United States) specializing in pharmacokinetics of monoclonal antibodies, oncology, and cancer pharmacology.

Publications per year

2017–2019

4

Publications

4

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors

Gentry Teng King, Keith D. Eaton, Brandon Beagle et al. · Investigational New Drugs · 2018 · 87 citations · Full text

, , +15

First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors

Ignacio Garrido‐Laguna, Ian E. Krop, Howard A. Burris et al. · International Journal of Cancer · 2019 · 53 citations · Full text

, , +17

A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.

Ignacio Garrido‐Laguna, Ian E. Krop, Howard A. Burris et al. · Journal of Clinical Oncology · 2017 · 11 citations

, , +15

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors

Pamela Farrell, Christopher J. Zopf, Huey-Jing Huang et al. · Journal of Pharmacology and Experimental Therapeutics · 2019 · 10 citations · Full text

, , +16

1–4 of 4